Article
Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options.
Blood - 23 Dec 2021
Malcikova Jitka, Pavlova Sarka, Kunt Vonkova Barbara, Radova Lenka, Plevova Karla, Kotaskova Jana, Pal Karol, Dvorackova Barbara, Zenatova Marcela, Hynst Jakub, Ondrouskova Eva, Panovska Anna, Brychtova Yvona, Zavacka Kristyna, Tichy Boris, Tom Nikola, Mayer Jiri, Doubek Michael, Pospisilova Sarka
Abstract excerpt
Patients with chronic lymphocytic leukemia (CLL) bearing TP53 mutations experience chemorefractory disease and are therefore candidates for targeted therapy. However, the significance of low-burden TP53 mutations with <10% variant allele frequency (VAF) remains a matter for debate. Herein, we describe clonal evolution scenarios of low-burden TP53 mutations, the clinical impact of which we analyzed in a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.